I started at CNBC 23 years ago today. One early big story I covered was Katrina 20 years ago, when I grossed out the control room reporting on a company that decontaminated water. We took some from a yucky puddle, treated it with solution and then I drank it. Nothing like hearing "Eww" in your ear!

HHS HRT announcement: "After more than two decades of fear and misinformation surrounding hormone replacement therapy... the U.S. Food and Drug Administration... is initiating the removal of broad 'black box' warnings from HRT products for menopause." www.hhs.gov/press-room/f...

Insurers are down because a one-year tax credit extension won't stabilize the ACA market. Folks on the federal exchange have until December 15th to sign up. Next year passing credits at year-end does nothing to resolve uncertainty for setting 2027 rates. A "Doc Fix' cadence won't work for insurance.

Insurers are down because a one-year tax credit extension credits won't stabilize ACA market. Folks on the federal exchange have until December 15th to sign up. And passing credits at year-end does nothing to resolve uncertainty for setting 2027 rates. A "Doc Fix' cadence won't work for insurance.

Maybe we really could be entering a new era when a drugmaker touts not just efficacy but affordability. The sub-headline in the NYT report is that Merck’s new cholesterol “drug targets the PCSK9 protein, and could give millions of people a more affordable option to reduce their heart disease risk.”

I asked Pres. Trump about the bipartisan discussions to extend the tax credits in Congress. "I don't weigh in," he said. "But we're looking at all of that right now. We're looking at all of it. There are a lot of great ideas out there, including for health care, because Obamacare is a disaster."

yikes!

Bloomberg looks at 46brooklyn analysis of Cigna's generic drug subsidiary Quallent's prices vs those of competitors: "Quallent’s drugs are typically 33 times more expensive than the cheapest option in the category, 46brooklyn found." Cigna calls data flawed.

I was this many days old before I ever got to report from the White House, with a great CNBC crew!

Novo shares are down nearly 4%. This don’t not replace the IRA price negotiations. And also NVO is already facing pricing pressure.

CMS Administrator Dr. Oz says TrumpRx should be up by the end of the year for seeing prices.

Cash pay will be available on TrumpRx starting in 2026, when that launches.

President Trump announcing MFN Deal. Calls LLY’s David Ricks a friend who helped start the process.

The ACA Marketplace Open Enrollment season began November 1. With it comes looming changes to the enhanced premium tax credits, higher premium payments, changes to Marketplace eligibility rules, and more. Our updated ACA resources can help guide you through the changes: https://on.kff.org/3NPfMfE

When you're anticipating news on GLP-1s, after multiple reports... and then this ad pops up.

The price pressures could mount, with reports the Trump admin has struck a GLP-1 MFN deal, the IRA Medicare discount on semaglutide set to begin in 2027 and generics coming onto the market in Canada next year.

And they actually roomed together in DC, according to the NYT.

Lousiana, the home state of the House Speaker

How concerned are people about rising health insurance premiums? With premium tax credit enhancements about to expire and ACA marketplace open enrollment underway, search volumes for terms like “health premium increase” are (almost) off the charts.

Novo Nordisk shares under pressure on reports the Trump administration close to an MFN deal with Novo and Eli Lilly to bring price of GLP-1s for obesity to $149. Novo also faces lower Medicare pricing in 2027 under IRA negotiations which ended Oct. 31st.

Being told "you're dead" via snail mail...

Experts worry FDA’s credibility is being shredded by scandal and ‘soap opera’ www.statnews.com/2025/11/04/f...

Health insurers bucking the trend today, led by Centene. Barclays raising its target on CNC to $44 from $35. I'll be speaking with Centene CEO Sarah London tomorrow at the @milkeninstitute.org Future of Health Summit.

Yamamoto was way more than “daijoubu” — truly historic. My stomach was in knots the whole time. Such a great story of hope, determination and talent.

Un-be-liev-able comeback!!! Congrats to the Dodgers!!!!!

OMG!!! I need some Pepcid to literally stomach this game rn I don’t know how they hold it together on the field. #worldseries

Not that anyone asked me, but not buying looks 2 or 3. And the patterned blouse and sweater would look much better with straight leg jeans or pants.

Same day. 🇺🇸

SNAP benefits must continue despite shutdown, judge tells Trump administration

I like the print title for this article better: 'How Healthy Is My Gut? Let Me Count the Waste'

microsoft wants to use your linkedin data to train LLMs turn it off here: www.linkedin.com/mypreference...

So much health care at stake this Halloween: - it's now one month with no funding for telehealth in Medicare amid the shutdown - on the eve on ACA Open Enrollment, premiums are up overall, but with no deal on Enhanced tax credits middle class enrollees face effective price increases of up to 300%

Fitch on Tax Credit uncertainty:"This dynamic has led to higher base premium rate increases for the 2026 plan year to offset higher projected utilization rates. This uncertainty around 2026 utilization rates has heightened pricing and performance risks for insurers operating in the ACA marketplace."

RBC Analyst BEn hendrix calls CI selloff overdone: "We believe the PBM model changes are proactive and will support positioning in the longer term.. our valuation thesis is underpinned by strong growth in Specialty, which remains on track for earnings growth near the high end of.. range next year."

About that new transparent PBM business model... CVS Q3 beat but stock getting bruised after CFO Brian Evanko said on the earnings call "the transitional and investment spend associated with our new rebate-free model -- this will result in margin pressure across 2026 and 2027."

Confirmation hearing for Trump’s surgeon general nominee, Casey Means, is postponed… as she goes into labor From @owermohle.bsky.social www.cnn.com/2025/10/30/h...

It’s a strategic move as its semaglutide is set to go generic next door in Canada, and the IRA will slash the price in Medicare starting in 2027.

Seems Wegovy has not curbed Novo Nordisk’s appetite when it comes to weight loss drugs.

Trump’s demolition of the East Wing + construction of his ballroom is broadly unpopular. 56% of Americans oppose the project, compared to 28% who support it, per new Post-ABC-Ipsos poll. with @abtran.bsky.social @jonathanreports.bsky.social @sfcpoll.bsky.social

That was the first trial I ever covered. I was a reporter trainee and I would take notes on the testimony, so that he could find the soundbites he needed for his story. It was great training for developing an ear for key soundbites.

Centene surging on Q3 beat and raised 2025 outlook, as insurers under pressure. CNC CEO Sarah London is confident on the outlook for the company's ability to navigate ACA next year with or without enhanced tax credits. We'll hear from Obamacare rivals Cigna tomorrow, and Oscar Health next week.

Centene CEO Sarah London on earnings call says went after Medicaid cost pressures, in FL shared real-time cost data and the state boosted reimbursment; in NY identified a mental health provider with fraudulent claims and along with state terminated that contract.

CVS shares rising with earnings call, CFO Brian Newman offering more color on MBR: Our medical benefit ratio this quarter was impacted by approximately 100 basis points due to provider liabilities. For matters dating as far back as 2018 and worsening individual exchange risk adjustment expectations

Centene surging after reporting a surprise profit and raised outlook. Q3 adj. $0.50 vs loss of $0.14 est. Health Benefits Ratio (HBR) a slight beat: 92.7% vs 92.9%. Costs in Medicaid "driven primarily by behavioral health and home health, partially offset by Medicaid rate and revenue increases"

CVS shares flat after posting third consecutive beat and raise one year into CEO David Joyner's tenure, with record revenue marking company's first quarter topping $100B. Q3 adj $1.60 vs $1.37 est. on Rev. $102.87B vs. $98.85B est. Ups full year 2025 outlook to adj. $6.55-$6.65 vs. $6.38 est.

Eli Lilly, Nvidia partner to build supercomputer, AI factory for drug discovery and development

AMZN, UPS and Chegg.... we may all be John Henry vs the steam driver soon enough... Though, I have to think that there are some things where people still want people. I don't want a robot or robotic doctor.

On call UNH CEO Steve Hemsley says UHC is on track for margin improvement in 2026.. "In our less mature businesses such as Optum Health and Optimum Insight. Our efforts to improve operations and make needed investments will show more measured progress... and l take more time to fully bear fruit."

Page One in Detroit: @freep.com

UnitedHealth Q3 beats: $2.92 eps vs $2.79 est. Revs. $113.2 B vs $113 B est. -Raises 2026 guide to at least $16.25 eps vs $16.20 est. Results driven by better than expected $87.1 B UnitedHealthcare insurance revenues, Medical cost ratio 89.9% 80 bps better than expected.